Related Experiment Video
Updated: Jul 25, 2025
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A
Ulrik Lassen1, Carsten Bokemeyer2, Jesus Garcia-Foncillas3
1Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Purpose:
Evidence suggests that neurotrophic tyrosine receptor kinase (NTRK) gene fusions in solid tumors are predictive biomarkers for targeted inhibition across a number of adult and pediatric tumor types. However, despite robust clinical response to tyrosine receptor kinase (TRK) inhibitors, the natural history and prognostic implications of NTRK fusions in solid tumors are poorly understood. It is important to evaluate their prognostic significance on survival to provide some context to the clinical effectiveness observed in clinical trials of TRK-targeted therapies.
Methods:
A systematic literature review was conducted in Medline, Embase, Cochrane, and PubMed to identify studies comparing the overall survival (OS) of patients with NTRK fusion-positive (NTRK+) versus NTRK fusion-negative (NTRK-) tumors. Five retrospective matched case-control studies published before 11 August 2022 were assessed for inclusion, and three were selected for the meta-analysis (sample size: 69 NTRK+, 444 NTRK-). Risk of bias was assessed using the Risk of Bias Assessment tool for Non-randomized Studies tool. The pooled hazard ratio (HR) was estimated using a Bayesian random-effects model.
Results:
In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK-, the pooled HR estimate for OS was 1.51 (95% credible interval, 1.01 to 2.29). The patients analyzed had no previous or current exposure to TRK inhibitors.
Conclusion:
In patients not treated with TRK inhibitor therapies, those with NTRK+ solid tumors have a 50% increased risk of mortality within 10 years from diagnosis or the start of standard therapy compared with those with NTRK- status. Although this is the most robust estimate of the comparative survival rate to date, further studies are required to reduce uncertainty.
Insights
Patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusions in solid tumors face a 50% higher mortality risk if untreated. This study clarifies the prognostic impact of NTRK fusions on survival for these patients.
Area of Science:
- Oncology
- Genetics
- Biomarkers
Background:
- Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are key biomarkers in various solid tumors, predicting response to targeted therapies.
- The natural history and prognostic implications of NTRK fusions remain poorly understood, necessitating survival analysis.
Approach:
- A systematic literature review identified retrospective studies comparing overall survival (OS) in NTRK fusion-positive (NTRK+) versus NTRK fusion-negative (NTRK-) tumors.
- Three studies were included in a meta-analysis using a Bayesian random-effects model to estimate the pooled hazard ratio (HR) for OS.
Key Points:
- The meta-analysis included 69 NTRK+ and 444 NTRK- patients, with median follow-up of 2-14 years.
- Untreated patients with NTRK+ solid tumors showed a 1.51-fold increased risk of mortality (HR: 1.51; 95% CI: 1.01–2.29) compared to NTRK- patients.
Conclusions:
- NTRK gene fusions are associated with a significantly increased mortality risk in patients with solid tumors who have not received TRK inhibitor therapy.
- Further research is needed to reduce uncertainty and fully elucidate the prognostic significance of NTRK fusions.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...